DocMorris Raises 2026 Guidance After Strong First‑Half Growth
DocMorris (ticker SIX:DOCM) announced that its external revenue for the first half of 2026 rose 12.5% in local currency to CHF 627.8 million. Adjusted EBITDA improved by CHF 17.9 million year‑on‑year, narrowing the loss to CHF 10.9 million.
Revenue from prescription medicines increased 38.3% year‑on‑year, accelerating to a 45.8% rise in the second quarter, driven by higher customer loyalty, repeat orders and new customer acquisition. Consequently, the company now expects full‑year prescription‑medicine growth of around 40%, up from its earlier forecast of roughly 20%.
Digital Services revenue surged 71.4% year‑on‑year, and EBITDA doubled. This performance led DocMorris to raise its full‑year growth forecast for digital services to more than 50%.
The firm lifted its 2026 external‑revenue growth guidance to a range of 9%‑13%, revising the prior outlook of mid‑single‑digit to low‑teens. The adjusted EBITDA loss forecast was narrowed to a range of CHF 10 million‑CHF 17.5 million, compared with the earlier range of CHF 10 million‑CHF 25 million.
Capital expenditure for 2026 is expected to remain below CHF 30 million. Management reaffirmed its target to achieve free‑cash‑flow breakeven in 2027.